Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout
ModernaMRNAannounced that it entered a definitive agreement to acquire Japan-based OriCiro Genomics (“OriCiro”) for $85 million. The acquisition of OriCiro looks like a strategic fit for Moderna, as the company is focused on expanding and boosting its mRNA-manufacturing capabilities. It expects OriCiro’s proprietary technologies to support its portfolio of mRNA-based therapeutics and vaccines. OriCiro is […]
Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout Read More »